Selected research
Industry Growth & Trends
Global Hepatic Encephalopathy (HE) Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Hepatic Encephalopathy (HE) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Hepatic Encephalopathy (HE) Therapeutics market include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Hepatic Encephalopathy (HE) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Hepatic Encephalopathy (HE) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatic Encephalopathy (HE) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatic Encephalopathy (HE) Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Hepatic Encephalopathy (HE) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Hepatic Encephalopathy (HE) Therapeutics Market by Company
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant
Hepatic Encephalopathy (HE) Therapeutics Segment by Type
Probiotics
Neomycin
Lactulose
Thiamine
Rifaximin
Hepatic Encephalopathy (HE) Therapeutics Segment by Application
Acute Liver Failure
Liver Cirrhosis
Hepatic Encephalopathy (HE) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy (HE) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy (HE) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy (HE) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Probiotics
- Neomycin
- Lactulose
- Thiamine
- Rifaximin
Applications
- Acute Liver Failure
- Liver Cirrhosis
Companies covered
- ASKA Pharmaceutical
- COSMO PHARMACEUTICALS
- Mallinckrodt
- Valeant
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
- 1.5.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2021-2032)
2 Hepatic Encephalopathy (HE) Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Probiotics
- 2.1.2 Neomycin
- 2.1.3 Lactulose
- 2.1.4 Thiamine
- 2.1.5 Rifaximin
- 2.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
- 2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions
- 2.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Hepatic Encephalopathy (HE) Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Acute Liver Failure
- 3.1.2 Liver Cirrhosis
- 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
- 3.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions
- 3.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends
- 4.2 Hepatic Encephalopathy (HE) Therapeutics Industry Drivers
- 4.3 Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges
- 4.4 Hepatic Encephalopathy (HE) Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Hepatic Encephalopathy (HE) Therapeutics Revenue (2021-2026)
- 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Hepatic Encephalopathy (HE) Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Hepatic Encephalopathy (HE) Therapeutics Company, Product Type & Application
- 5.5 Global Hepatic Encephalopathy (HE) Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Hepatic Encephalopathy (HE) Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Hepatic Encephalopathy (HE) Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Hepatic Encephalopathy (HE) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 ASKA Pharmaceutical
- 6.1.1 ASKA Pharmaceutical Company Information
- 6.1.2 ASKA Pharmaceutical Business Overview
- 6.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
- 6.1.5 ASKA Pharmaceutical Recent Developments
- 6.2 COSMO PHARMACEUTICALS
- 6.2.1 COSMO PHARMACEUTICALS Company Information
- 6.2.2 COSMO PHARMACEUTICALS Business Overview
- 6.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
- 6.2.5 COSMO PHARMACEUTICALS Recent Developments
- 6.3 Mallinckrodt
- 6.3.1 Mallinckrodt Company Information
- 6.3.2 Mallinckrodt Business Overview
- 6.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
- 6.3.5 Mallinckrodt Recent Developments
- 6.4 Valeant
- 6.4.1 Valeant Company Information
- 6.4.2 Valeant Business Overview
- 6.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
- 6.4.5 Valeant Recent Developments
7 North America
- 7.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst